FDA Grants Accelerated Approval for RRP Immunotherapy

The FDA has granted accelerated approval to Voceryq, a plasmid DNA-based immunotherapy, for adults with recurrent respiratory papillomatosis (RRP). This treatment aims to reduce the frequency of surgical excisions required for this rare, debilitating HPV-related disease. Continued approval is contingent on confirmatory studies verifying its clinical benefit, offering a new therapeutic approach for patients.